The Impact of Clostridium Histolyticum Collagenase on the Prevalence and Management of Peyronie's Disease in the United States
Open Access
- 1 January 2019
- journal article
- research article
- Published by XMLink in The World Journal of Men's Health
- Vol. 37 (2) , 234-239
Abstract
Sun AJ, et al. World J Mens Health. 2018 Jan;36:e47. https://doi.org/10.5534/wjmh.180073Keywords
This publication has 16 references indexed in Scilit:
- Intralesional Injection of Collagenase Clostridium histolyticum May Increase the Risk of Late-Onset Penile FractureSexual Medicine Reviews, 2018
- Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy with Collagenase Clostridium Histolyticum for Peyronie’s DiseaseThe Journal of Sexual Medicine, 2016
- Peyronie’s Disease: AUA GuidelineJournal of Urology, 2015
- Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 StudiesJournal of Urology, 2013
- Psychological Impact of Peyronie's Disease: A ReviewThe Journal of Sexual Medicine, 2013
- A Population-Based Study of Peyronie's Disease: Prevalence and Treatment Patterns in the United StatesAdvances in Urology, 2011
- Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled studyInternational Urology and Nephrology, 2009
- The prevalence of Peyronie's disease in diabetic patients with erectile dysfunctionInternational Journal Of Impotence Research, 2006
- Prevalence of Peyronie’s Disease Among Patients With Erectile DysfunctionEuropean Urology, 2006
- Use of Intralesional Verapamil to Dissolve Peyronie’s Disease Plaque: A Long-Term Single-Blind StudyUrology, 1998